Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1096 | 1085 | 1209 | 1233 | 1948 | 3049 |
Fund Return | 9.55% | 8.46% | 20.86% | 7.23% | 14.26% | 11.79% |
Place in category | 166 | 152 | 74 | 43 | 28 | 11 |
% in Category | 89 | 82 | 40 | 25 | 18 | 8 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LansfOrsakringar Global Indexnara | 97.12B | 15.06 | 15.50 | 14.22 | ||
Lansforsakringar USA Indexnara | 38.59B | 17.51 | 18.75 | 17.56 | ||
Lansforsakringar Sverige Indexnara | 35.76B | 10.58 | 4.90 | 9.57 | ||
Lansforsakringar Global Hallbar A | 23.52B | 19.03 | 14.60 | 12.32 | ||
Lansforsakringar Global Hallbar B | 23.52B | 19.18 | 14.94 | 12.57 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Handelsbanken Sverige Index A1 SEK | 66.52B | 11.64 | 4.83 | 10.18 | ||
Handelsbanken Sverige Index B1 SEK | 66.52B | 11.64 | 4.83 | 9.71 | ||
Folksam LO Sverige | 54.01B | 7.01 | 9.53 | 9.85 | ||
Avanza Zero | 50.43B | 10.94 | 8.26 | 9.75 | ||
Swedbank Robur Sverigefond | 48.21B | 10.48 | 11.61 | 9.23 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Investor B | SE0015811963 | 8.53 | 287.0 | -0.09% | |
Hexagon B | SE0015961909 | 5.35 | 116.53 | +0.00% | |
Volvo B | SE0000115446 | 5.25 | 281.50 | -1.54% | |
AstraZeneca | GB0009895292 | 4.97 | 12,528.0 | -0.49% | |
Nordea Bank | FI4000297767 | 4.90 | 11.410 | +0.13% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Strong Buy | Buy |
Technical Indicators | Strong Sell | Strong Buy | Strong Buy |
Summary | Sell | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review